Physician profile
Natisha Ram
NPI 1104471036
$1,423.02
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $307 · 2023: $1,094 · 2024: $22.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.18 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $281.64 | 2022-2023 | Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $252.06 | 2022-2023 | Dupixent |
| Amgen INC. | $141.94 | 2022-2023 | Tezspire |
| Abbvie INC. | $99.51 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $98.99 | 2023 | |
| Kaleo, INC. | $90.06 | 2023 | Auvi-Q |
| Glaxosmithkline, LLC. | $77.41 | 2022-2023 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $63.00 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $52.01 | 2023 | |
| Alk-Abello, INC | $49.76 | 2023 | Grastek, Odactra |
| Csl Behring | $49.02 | 2023 | Hizentra |
| Genentech USA, INC. | $34.34 | 2023 | Xolair |
| Teva Pharmaceuticals USA, INC. | $33.73 | 2022 | |
| Aimmune Therapeutics, INC. | $26.98 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.73 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natisha Ram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.